24916 Efficacy of ruxolitinib cream in patients with atopic dermatitis who demonstrated partial responses: Pooled analysis from two randomized phase 3 studies

Abstract

Ruxolitinib cream is a Janus kinase (JAK) 1/JAK2 inhibitor in development for atopic dermatitis (AD). Two phase 3 randomized studies (TRuE-AD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment (IGA) score of 2 or 3, and 3%-20% affected body surface area. Patients (N = 1249 in both studies combined; median age, 32 years) were randomized (2:2:1) to twice-daily 0.75% ruxolitinib, 1.5% ruxolitinib, or vehicle cream for 8 weeks of double-blinded treatment.